Fallopian Tube Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Primary fallopian tube carcinoma (PFTC) is rare cancer that arises from the transformation of the salpingeal mucosa, or the cells lining the fallopian tubes. The exact cause of PFTC is unknown, but hormonal, reproductive, and genetic factors, as well as deleterious mutations in the BRCA1 or BRCA2 genes, are thought to increase the risk of this disease. The most common type of PFTC is papillary serous adenocarcinoma, which represents more than 95% of fallopian tube cancers. Other types of PFTC include sarcomas (leiomyosarcomas) and transitional cell carcinomas. PFTC typically occurs between the ages of 40 and 60, with a median age of 55. Symptoms of PFTC include irregular vaginal bleeding or discharge, lower abdominal pain, bloating, and pelvic pressure. Pain, which may be relieved with the passage of blood or discharge, is a commonly reported symptom. The 5-year survival rate for patients with stage III-IV disease is 55% if the residual tumor is less than 1 cm in diameter, compared to 21% for those with larger residual tumors.
·
Fallopian tube cancer is a rare gynecologic
cancer, comprising only 1 to 2 percent of all cases. Around 300 to 400 women in
the United States are diagnosed yearly.
Thelansis’s “Fallopian Tube Cancer
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2022 To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Fallopian Tube Cancer treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Fallopian Tube Cancer across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Fallopian Tube Cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment